Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Streptozocin
Drug ID BADD_D02073
Description An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
Indications and Usage For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
Marketing Status approved; investigational
ATC Code L01AD04
DrugBank ID DB00428
KEGG ID D05932
MeSH ID D013311
PubChem ID 29327
TTD Drug ID D0I8RR
NDC Product Code 67430-225; 68118-100; 0703-4636
UNII 5W494URQ81
Synonyms Streptozocin | Streptozotocine | 2-Deoxy-2-((methylnitrosoamino)carbonyl)amino-D-glucose | Streptozotocin | Zanosar
Chemical Information
Molecular Formula C8H15N3O7
CAS Registry Number 18883-66-4
SMILES CN(C(=O)NC1C(C(C(OC1O)CO)O)O)N=O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insulinoma05.08.01.004; 07.21.09.001; 16.24.02.003---
Ketonuria20.02.01.009---
Lethargy08.01.01.008; 17.02.04.003; 19.04.04.004--
Leukopenia01.02.02.001---
Nausea07.01.07.001--
Necrosis08.03.03.001; 24.04.02.006---
Neoplasm malignant16.16.01.001---
Nephrogenic diabetes insipidus14.05.07.002; 20.05.03.010---
Nephropathy toxic12.03.01.010; 20.05.03.002---
Neutropenia01.02.03.004---
Oedema08.01.07.006; 14.05.06.010---
Pain08.01.08.004--
Pancytopenia01.03.03.003---
Platelet count decreased13.01.04.001--
Proteinuria20.02.01.011--
Renal tubular acidosis14.01.01.005; 20.05.03.003---
Road traffic accident12.01.08.006---
Shock hypoglycaemic05.06.03.003; 14.06.03.003---
Tenderness08.01.08.005---
Thrombocytopenia01.08.01.002---
Vomiting07.01.07.003--
Fanconi syndrome acquired14.01.01.013; 20.05.03.012---
Protein urine present13.13.02.006---
Hepatic enzyme increased13.03.04.028---
Haematotoxicity01.05.01.007; 12.03.01.025---
Inflammation08.01.05.007; 10.02.01.089---
Chronic kidney disease20.01.03.017--
Bone marrow failure01.03.03.005--
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene